Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

Ozempic is traditionally used as a treatment for type 2 diabetes (T2DM) to help patients manage blood sugar levels. However, ...

Rybelsus (semaglutide ... loss. Are there any long-term side effects of Rybelsus treatment? No, Rybelsus isn’t known to cause long-term side effects. And taking Rybelsus for a long period of ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth ... by the weight-loss profile of CagriSema." ...

Roxy Jacenko has revealed a new health scare almost 10 years after battling breast cancer. The PR mogul, 44, shared a video ...

Whether or not it’s true, the curiosity seems to reflect a real-life trend: Patients in their 40s seeking lifts by their ...